Cancer Science Institute (CSI) of Singapore

As one of only five institutions in Singapore awarded a $172 million “Research Centre of Excellence” grant by the government, the Cancer Science Institute (CSI) of Singapore at the National University of Singapore (NUS) is dedicated to investigating the pathogenesis of cancer and creating innovative, safer methods of diagnosis and treatment. Established on 15 October 2008, over 200 scientists and researchers engage in life-saving work daily at the institute spearheaded by Professor Daniel G. Tenen, a world-leader in the field of transcriptional regulation, hematopoiesis, and cancer.

Mission:
Our mission is to deliver research leading to better cancer prevention, diagnosis and treatment, by recruiting outstanding talent and providing world-class training programs to nurture the next generation of research innovators.

Core Values:
Devoted to the Cause They are committed to the fight against cancer. Our priority is to harness basic science discoveries to create more effective, as well as improve existing cancer treatments.

Research with a Focus:
Our areas of focus lie particularly in Aerodigestive Tracts Cancers, Breast and Female Cancers and Hematologic Malignancies, which are prevalent in Asian populations, along with a breast cancer working group examining Asian phenotypes.

Excellence:
They pursue excellence relentlessly and continually seek to innovate and revolutionize cancer research. In support of research excellence, CSI houses a full spectrum of basic and clinical translational facilities with a multitude of state-of-the-art core support technologies. These sophisticated technologies provide robust investigational resources for CSI and also the wider NUS community.

Collaborative Partnerships:
They are an advocate of collaborative partnerships both within the Institute and with other institutes. CSI works closely with basic scientists and clinicians across Singapore in various institutes, including the National University of Singapore (NUS), National University Hospital (NUH), National Cancer Institute Singapore (NCIS), Duke-NUS Graduate Medical School and Institute of Molecular and Cell Biology (IMCB). To accomplish our research goals, they initiated and lead the Frontiers in Cancer Science, an annual cancer conference offering researchers globally a major platform to engage in world-class scientific partnerships.

Inspiring:
They are dedicated to inspire and mentor the young researchers of today to produce an outstanding generation of scientists for tomorrow.